Skip to main content

Table 4 Prognostic factor analysis (univariate).

From: Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis

  OS (months) 95% CI P value
Age    
   < median 15.2 11.5 - 19.0 0.491
    median 12.8 7.1 - 18.4  
Gender    
   male 13.2 9.8 - 14.8 0.49
   Female 16.8 10.7 - 22.8  
Performance status    
   0-1 15.2 12.0 18.5 0.01
    2 7.6 0 - 16.5  
Disease status    
   Advanced 15.2 11.7 - 18.8 0.24
   Recurrent 12.1 9.1 - 15.1  
Histology    
   differentiated 14.5 9.1 - 18.2 0.357
   undifferentiated 14.6 11.0 - 18.2  
No. of organs involved    
   1 12.8 10.1 - 15.4 0.414
    2 16.9 14.4 - 19.3  
Liver metastasis    
   No 16.0 12.7 - 19.3 0.237
   Yes 10.4 3.5 - 17.3  
Peritoneum metastasis    
   No 15.1 9.5 - 20.7 0.54
   Yes 14.6 11.1 - 18.1  
Tumor response    
   No (SD or PD) 8.6 6.0 - 11.2 <0.001
   Yes (PR) 18.2 12.7 - 23.7  
Second-line chemotherapy    
   No 8.6 4.2 - 13.0 0.024
   Yes 16.3 15.0 - 17.5  
  1. OS, median overall survival